Clinical trials
Breast - Female clinical trials
Below are recruiting breast - female clinical trials, each written for real people, not researchers. We’re tracking 3,704 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT07743944Recruiting
Breast cancer second-line treatment patterns in China
This study looks at how doctors in China treat hormone receptor-positive, HER2-negative breast cancer that has spread, when patients are starting their second line of therapy. The goal is to learn more about real-world treatment patterns and results, which may help you and your doctor make more informed treatment decisions.
Nanjing, JiangsuAges 18 years+ - NCT07078604RecruitingPhase 2
Vaccine with chemotherapy for advanced triple-negative breast cancer
This trial tests a cancer vaccine called STEMVAC combined with chemotherapy in people with a type of breast cancer that has spread and does not have certain markers. The goal is to see if adding the vaccine helps the chemotherapy work better.
Seattle, WashingtonAges 18 years+ - NCT05863195RecruitingPhase 3
Pump chemotherapy plus standard chemo for liver-only colorectal spread
This study tests adding a chemotherapy “pump” directly into the liver along with standard chemotherapy, compared with standard chemotherapy alone. It’s for adults with colorectal cancer that has spread to the liver but cannot be surgically removed, and who are responding to first chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT03191149RecruitingPhase 2
Osimertinib for lung cancer with an EGFR exon 20 change
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
Anchorage, AlaskaAges 18 years+ - NCT07741435Recruiting
Simple blood, urine, and saliva test to find cancer early
This study tests a new way to find cancer by looking at DNA in blood, urine, and saliva. It may help detect cancer earlier and monitor how well treatment works.
Bogotá, Bogota D.C.Ages 18 years+ - NCT07743294Recruiting
Exercise before breast cancer surgery to reduce arm swelling
This trial tests whether doing specific exercises before breast cancer surgery helps reduce arm swelling (lymphedema) after surgery, and improves quality of life and care needs. You would participate in a supervised exercise program before your surgery and then follow up after.
TaipeiAges 20 years+ - NCT06885034RecruitingPhase 1/Phase 2
Testing a New Drug for Advanced Colon, Rectal, or Pancreatic Cancer
This study tests an experimental drug, alone or combined with other treatments, for advanced colon, rectal, or pancreatic cancer that hasn't responded to standard options or cannot be removed by surgery. The goal is to see if it is safe and if it helps shrink or slow the cancer.
Los Alamitos, CaliforniaAges 18 years+ - NCT06922708Recruiting
Using genetic risk scores to improve breast cancer prevention
This study is testing a new way to use your genetic information (along with your family history) to better understand your personal risk for breast cancer. The goal is to see if giving this risk report to women with higher genetic risk can help them and their doctors make more informed decisions about screening and prevention.
RomaAges 18–79 - NCT06680596Enrolling by invitationPhase 2
Blood test to find T-DXd candidates for breast cancer
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
AmiensAges 18 years+ - NCT04753970RecruitingPhase 1/Phase 2
Study uses retina changes to assess blood vessel health
This study looks at the back of your eyes (the retina) to see if it reflects blood vessel health in the brain. It may help doctors find easier ways to track conditions related to small blood vessel disease.
Jacksonville, FloridaAges 18 years+ - NCT07173751RecruitingPhase 3
Pumitamig for advanced triple-negative breast cancer
This study tests a new drug called pumitamig for people with a type of breast cancer that is triple-negative or has very low hormone receptors and has come back or spread. It aims to see if pumitamig works better than standard treatment and how safe it is for people who cannot get PD(L)-1 immunotherapy with chemo.
Springdale, ArkansasAges 18 years+ - NCT07673588Recruiting
Instagram and podcast study for breast cancer awareness in young women
This study tests whether combining Instagram posts with podcast episodes can help women aged 20-39 learn more about breast cancer and get recommended screenings. It aims to make health information easy to access and understand.
AnkaraAges 20–39 - NCT07319091Recruiting
Cystinosis and Mitochondrial Energy Study
This study looks at how cystinosis affects the energy centers (mitochondria) in your cells. It may help doctors understand how cysteamine treatment works in patients with kidney cystinosis.
BronAges 2 years+ - NCT05687110RecruitingPhase 1
Testing novobiocin for tumors with DNA repair gene changes
This Phase 1 study tests whether novobiocin is safe and finds the best dose for people whose tumors have specific DNA repair gene mutations. It may help if your cancer is hard to treat with standard options, including certain patients who already tried PARP inhibitors.
Duarte, CaliforniaAges 18 years+ - NCT07739121Recruiting
Testing AI vs. tumor boards for cancer treatment advice
This trial compares treatment recommendations from large language models (AI) against those from experienced tumor boards for five common cancer types. The goal is to see if AI can help doctors make better decisions.
ParisAges 18 years+ - NCT04816006Recruiting
Breast cancer, thinking, and exercise study
This trial tests whether exercise can help thinking and reasoning in women over 50 who have had early-stage breast cancer. It compares a moderate exercise program with health education sessions.
Phoenix, ArizonaAges 50 years+ - NCT06703073RecruitingPhase 2
Testing new treatments for acute respiratory distress syndrome (ARDS)
This trial is testing new treatments for people with ARDS, a serious lung condition. The goal is to find therapies that help patients breathe better and recover faster. If you or a loved one has ARDS, this study may offer access to experimental treatments.
Birmingham, AlabamaAges 18 years+ - NCT06708897RecruitingPhase 1
Study of lonitoclax for returning B-cell blood cancers
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Louisville, KentuckyAges 18 years+ - NCT04521764RecruitingPhase 1
Vaccine for Metastatic Breast Cancer
This trial tests a vaccine (MV-s-NAP) that is injected directly into a tumor to stimulate your immune system against breast cancer. It is for people with metastatic breast cancer that has spread despite prior treatments.
Rochester, MinnesotaAges 18 years+ - NCT07402343RecruitingPhase 2
Tarlatamab for small cell lung cancer brain metastases
This trial tests a new drug, tarlatamab, for people with small cell lung cancer that has spread to the brain. It aims to see if the drug can shrink brain tumors and help you live longer, especially if you have not had brain radiation before.
AmsterdamAges 18 years+ - NCT07340541RecruitingPhase 2
Personalized cancer therapy trial based on tumor markers
This trial tests new treatments that are chosen based on specific markers in your tumor. Researchers want to see if these personalized therapies work better than standard options.
New Haven, ConnecticutAges 18 years+ - NCT04747054RecruitingPhase 3
Radiation plus pembrolizumab for newly diagnosed metastatic head and neck cancer
This trial studies whether adding pembrolizumab (an immune system medicine) to radiation can improve outcomes in people newly diagnosed with metastatic head and neck squamous cell cancer. It may help the immune system better recognize and fight the cancer alongside radiation.
AvignonAges 18 years+ - NCT07646847Recruiting
A support program for people with cancer on immunotherapy
This study tests a program that helps people with cancer manage side effects and find resources for needs like food, transportation, or housing. It is for patients who are starting or recently started immunotherapy for certain cancers.
Basking Ridge, New JerseyAges 18 years+
Hear when a new Breast - Female trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast - female?
- Yes. Clin2 currently lists 3,704 recruiting breast - female studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast - female trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast - female trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.